SCHEMBL4869311

SCHEMBL4869311

O=C(O)C1CCN(c2ncccc2Cl)CC1O

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 3/20 0.55
RORC P51449 17/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5741442 0.88 RORC (0.52) MALT1RORC
SCHEMBL23611936 0.86 RORC (0.58) MALT1RORC
SCHEMBL4865937 0.83 RORC (0.55) MALT1RORC
SCHEMBL2421306 0.81 MALT1 (0.70) MALT1
SCHEMBL27642287 0.78 MALT1 (0.47) MALT1
SCHEMBL4869706 0.78 TRPV1 (0.75) MALT1
SCHEMBL4866190 0.78 TRPV1 (0.75) MALT1
SCHEMBL4866182 0.78 TRPV1 (0.75) MALT1
SCHEMBL4869691 0.78 TRPV1 (0.75) MALT1
SCHEMBL4866177 0.78 TRPV1 (0.75) MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101434596-A Novel azaheterocyclic amides useful for treating pain ABBOTT LAB (US) 2009-05-20 CN disclosed
US-20080153809-A1 NOVEL AMIDES USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2008-06-26 US disclosed
US-7348343-B2 Amides useful for treating pain ABBOTT LABORATORIES INC. (US) 2008-03-25 US disclosed
US-20070010557-A1 Novel amides useful for treating pain ABBVIE INC. 2007-01-11 US disclosed
US-7129235-B2 Amides useful for treating pain ABBOTT LABORATORIES (US) 2006-10-31 US disclosed
CN-1849315-A Novel nitrogen-containing heterocyclic amides for the treatment of pain ABBOTT LAB (US) 2006-10-18 CN disclosed
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I ABBVIE INC. 2005-04-14 US disclosed
US-20050009841-A1 Novel amides useful for treating pain ABBOTT LABORATORIES 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009841-A1 Novel amides useful for treating pain OPRL1, OPRK1, FAAH2 MALT1 4880/4885RORC 2847/4885
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I TRPV1, OPRL1, TRPV6 MALT1 1308/4885RORC 1084/4885
US-20070010557-A1 Novel amides useful for treating pain OPRL1, PDE6B, PDE6G MALT1 3594/4885RORC 2586/4885
US-20080153809-A1 NOVEL AMIDES USEFUL FOR TREATING PAIN OPRL1, OPRK1, OPRD1 MALT1 4784/4885RORC 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.